Board of Directors
Tim Boris, Esq.
Mr. Boris is an experienced general counsel and business executive who has served on or been a legal advisor to executive and leadership teams in multiple industries. He joined the Vogenx board of directors in 2022. Mr. Boris currently serves as General Counsel for Elucida Oncology, Inc. and also serves on its Board of Directors. He also serves on the board of directors for Lipidio Pharmaceuticals. Mr. Boris received a Bachelor’s of Business Administration from the University of Michigan, Ross School of Business, and a juris doctorate from the University of San Diego School of Law.
Steven Delmar
Mr. Delmar serves as the Vogenx Chief Financial Officer and is a member of the Company’s board of directors. He has over two decades of public company CFO and executive management experience in the pharmaceutical, telecommunications, and software industries. During that time, Steve successfully led several debt and equity financings, including an IPO, and managed the execution and integration of multiple acquisitions and private equity sale transactions. Mr. Delmar earned a Bachelor of Science in Accounting from Clemson University and passed the CPA exam in Maryland.
Richard Gorman
Mr. Gorman joined the Vogenx board of directors in 2022 and currently serves as the President of Global Consulting at Envision Pharma Group. He brings extensive biopharmaceutical experience across several functional areas, has special expertise in business development and commercial strategy and is a well-regarded commercial voice within the pharmaceutical industry. Rich holds a BS from John Carroll University and an MBA from University of South Florida.
James Green
Mr. Green is the Chief Executive Officer of Vogenx and serves as Chairman of the Vogenx board of directors. James spent the early part of his career in banking where he advised on M&A and financing transactions. He then spent several years in various transaction related business development and finance roles at global pharmaceutical company GlaxoSmithKline. Prior to Vogenx, James was CEO of both public and private clinical stage drug development companies and developed an internal biotech investing platform at a pharmaceutical contract manufacturer. James holds a BBA and MBA.
Robert Ruffolo, PhD.
Dr. Ruffolo joined the Vogenx board of directors in 2022. He is the retired President of Research and Development and Corporate Senior Vice President of Wyeth Pharmaceuticals (now Pfizer) where he managed an R&D organization of 9,000 scientists with an annual budget in excess of $3 billion. Prior to that he spent 17 years at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) where he was Senior Vice President and Director of Biological Sciences Worldwide, and before that he spent six years at Eli Lilly Co. as Chairman of the Cardiovascular Research Committee. Dr. Ruffolo was responsible for the discovery of carvedilol (Coreg/Dilatrend) which radically changed the treatment of congestive heart failure by markedly reducing mortality and hospitalization from this devastating disease. For this he was awarded the Discoverers Award by PhRMA. During his career, Dr. Ruffolo has overseen the discovery, development, regulatory approval and marketing of over 30 drugs. He has published over 500 full-length publications, edited 15 books, served as Editor-in-Chief of four international scientific journals and has been a member of the editorial boards of 29 international scientific journals. Dr. Ruffolo currently serves on the boards of directors of Sigilon Therapeutics, Sapience Therapeutics, Elucida Oncology, Elicio Therapeutics, Lipido Pharmaceuticals, LB Pharmaceuticals, Aridis Pharmaceuticals, and Aragen Life Sciences. Dr. Ruffolo received both a B.S. degree in Pharmacy and a Ph.D. in Pharmacology from The Ohio State University.
Peter Pieraccini
Mr. Pieraccini is President and CEO of ZenBio. He joined the Vogenx board of directors in 2022. Over the last two decades, he has served as the founder or co-founder and chief executive of multiple companies covering a diverse array of industries. He has also engaged teams of investors in identifying and acquiring businesses and making them profitable. Mr. Pieraccini received his B.S. in accounting from Christian Brothers University
William Wilkison, PhD
Dr. Wilkison is the Vogenx Chief Scientific Officer, Chair of the Company’s Scientific Advisory Board, and member of the Vogenx board of directors. Before joining Vogenx, Bill was a founder and senior executive at various private and public drug development companies where he was responsible for overall pipeline strategy and oversight of all research and development activities. Dr. Wilkison spent several years at GlaxoSmithKline in Worldwide Business Development and at predecessor companies studying metabolic disease where he was responsible for target and lead identification and development. Dr. Wilkison has published numerous peer-reviewed manuscripts in the metabolic disease area and is an inventor on several issued and pending patents. Dr. Wilkison holds a Ph.D. from Duke University Medical Center and did his postdoctoral work at Harvard Medical School.